Suchergebnisse - "Ding, Xiaoyan"

PubPharm (13)

1

Treatment options for unresectable hepatocellular carcinoma with hepatitis virus infection following sorafenib failure

enthalten in: Cancer immunology, immunotherapy : CII | 2023

von Li, X. | Ding, X. | Li, W. | +1

2

Treatment options for unresectable hepatocellular carcinoma with hepatitis virus infection following sorafenib failure

enthalten in: Cancer immunology immunotherapy | 2022

von Li, X. | Ding, X. | Li, W. | +1

3

Prognostic models for outcome prediction in patients with advanced hepatocellular carcinoma treated by systemic therapy : a systematic review and critical appraisal

enthalten in: BMC cancer | 2022

von Li, L. | Li, X. | Li, W. | +4

4

Transarterial chemoembolization plus lenvatinib versus transarterial chemoembolization plus sorafenib as first-line treatment for hepatocellular carcinoma with portal vein tumor thrombus : A prospective randomized study

enthalten in: Cancer | 2021

von Ding, X. | Sun, W. | Li, W. | +7

5

RETRACTED ARTICLE: IL-2 augments the sorafenib-induced apoptosis in liver cancer by promoting mitochondrial fission and activating the JNK/TAZ pathway

enthalten in: Cancer cell international | 2018

von Ding, X. | Sun, W. | Chen, J.

6

RETRACTED ARTICLE: IL-2 augments the sorafenib-induced apoptosis in liver cancer by promoting mitochondrial fission and activating the JNK/TAZ pathway

enthalten in: Cancer cell international | 2018

von Ding, X. | Sun, W. | Chen, J.

7

IL-2 augments the sorafenib-induced apoptosis in liver cancer by promoting mitochondrial fission and activating the JNK/TAZ pathway

enthalten in: Cancer cell international | 2018

von Ding, X. | Sun, W. | Chen, J.

RetractionIn: Cancer Cell Int. 2019 Dec 30;19:358. - PMID 31892857

8

Sorafenib exerts an anti-keloid activity by antagonizing TGF-β/Smad and MAPK/ERK signaling pathways

enthalten in: Journal of molecular medicine (Berlin, Germany) | 2016

von Wang, W. | Qu, M. | Xu, L. | +7

9

Sorafenib exerts an anti-keloid activity by antagonizing TGF-β/Smad and MAPK/ERK signaling pathways

enthalten in: Journal of molecular medicine | 2016

von Wang, W. | Qu, M. | Xu, L. | +7

10

Sorafenib exerts an anti-keloid activity by antagonizing TGF-β/Smad and MAPK/ERK signaling pathways

enthalten in: Journal of molecular medicine | 2016

von Wang, W. | Qu, M. | Xu, L. | +7